The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety comprising a one or more peptides that are derived from a complementarity-determining region (CDR) from an antibody that interacts with a disease-specific or disease-related antigen, and a protein-binding moiety which is capable of binding to a carrier molecule.
